Ariana Pharma offers in silico models predicting the sensitivity and resistance of patients to reference treatments. These predictive models are implemented in Ariana’s Onco KEM® platform and rank the therapeutics based on their efficacy score computed from the individual profile of each patient. This tool is a clinical decision support system that generates specific treatment options for each patient through the delivery of an explanatory report.
Ariana is currently developing a set of software combined with laboratory tests that enable personalized treatment selection in oncology. Ariana has also developed algorithms that have been embedded in personalized medicine diagnostic tools. Ariana conducts these projects through partnerships with pharmaceutical and diagnostic companies as well as academic partners.
Ariana’s technology and expertise are also offered through consulting and data analysis services as well as licensing agreements for the KEM® software suite. Ariana’s team is multidisciplinary and highly experienced with degrees in Medicine, Computational Biology, Biostatistics, Biomathematics and Artificial Intelligence. Founded in 2003 as a spin-off of Institut Pasteur, Ariana is based in Paris and has a fully owned subsidiary in the U.S. It has entered into a distribution agreement with a Japanese provider, CT-LS.